News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Natalie S. Callander, MD, University of Washington Carbone Cancer Center

Articles by Natalie S. Callander, MD, University of Washington Carbone Cancer Center

BCMA-Targeted Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BELLINI Trial; Venetoclax-Vd in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

BOSTON Study; SVd in Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Lenalidomide-Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Daratumumab With Carfilzomib in Frontline Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Management of Relapsed/Refractory Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Maintenance Therapy Approaches in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

MRD Monitoring in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

The Role of Transplant in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Treating Transplant-Eligible and -Ineligible MM

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Transplant-Ineligible Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Tolerability of Triplet Therapy in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Frontline Triplet Therapies in Multiple Myeloma

ByKeith Stewart, MB, CHB, UHN and Princess Margaret Hospital,Natalie S. Callander, MD, University of Washington Carbone Cancer Center ,Thomas G. Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center,Noopur Raje, MD, Massachusetts General Hospital,Peter Voorhees, MD

July 17th 2020

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC

Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM

Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma

Dana-Farber Study Finds Dual Immunotherapy May Help Certain Patients With Advanced NSCLC Live Longer